The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive. Pfizer presently has a stellar rank, in the top 10% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.Start slideshow: 10 Oversold Dividend Stocks »But makin ...

I am a full-time analyst interested in a wide range of stocks. With my unique insights and knowledge, I hope to provide other investors with a contrasting view of my portfolio, given my particular background.If you have any questions, feel free to reach out to me via a direct message on Seeking Alpha or leave a comment on one of my articles.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the ...

One stock yields 6% today. Another has grown its dividend by 460% over the past decade. Both are blue chip bargains to buy right now.There is a lot of money flowing through the U.S. healthcare industry. According to the Centers for Medicare & Medicaid Services, America's total health expenditures were $4.1 trillion in 2022, and that number has likely increased since then. People have always, and will always, need care, so healthcare is a great place to look for dividend stocks.Pharmaceuticals and insurance ...

Pfizer is trading above its 52-week low but is still a dirt cheap buy.If you're looking for an undervalued growth stock to buy right now, Pfizer (PFE 0.47%) is an investment that should be near the top of your list. While the company is facing a challenging road ahead, I'm optimistic that it can continue generating good growth with the investments and moves it has been making in recent years.Investors may be down on the company, assuming that the business will be doomed as COVID-related sales decline and pa ...

An activist investor has correctly identified a dysfunctional area of the business.This is a bit of a trying time for Pfizer (PFE -1.18%). While the last 12 months saw the stock market provide a stunning total return of 41%, the struggling pharmaceutical giant returned a piddling 1%.Raining on the parade even more, Pfizer just reported some good news that seems to confirm the presence of some internal issues. So let's examine this new green flag that's also a red flag for anyone looking to buy the stock.It ...

On Oct. 29, Pfizer (PFE) announced third-quarter results, beating estimates for earnings as well as sales. Revenues rose 32% on an operational basis, driven by higher sales of key non-COVID products like Vyndaqel and Eliquis, new product launches and newly acquired products from Seagen.Sales of COVID products were higher than expected, driving most of the outperformance. Drugs added from last year’s Seagen acquisition contributed $854 million to the top line in the third quarter. Revenues from Pfizer’s non- ...

Wall Street's bearish take on this proven innovator may not be warranted. The Federal Reserve's ongoing rate-cutting cycle is already triggering a major shift in investor sentiment. As yields on fixed-income investments decline, institutional investors are clearly rotating into dividend-paying stocks, particularly those trading at reasonable valuations and above-average yields. In fact, several high-yield dividend stocks have outperformed the S&P 500 in 2024. This environment makes Pfizer's (PFE -0.74%) hef ...

Slowly but surely, the company's prospects are looking more attractive.The past three years have been disappointing for Pfizer (PFE -0.74%): The drugmaker's revenue, earnings, and stock price have generally moved in the wrong direction. However, it hasn't been all bad -- Pfizer has made some progress on the clinical and regulatory fronts with several brand-new approvals.And now the company's financial results are improving. Let's look into Pfizer's latest quarterly update and decide whether its shares are w ...

Core Viewpoint - Pfizer's stock has seen a modest increase of 1.9% this year, and several upcoming catalysts could potentially drive its stock price higher before the end of 2024 [1] Group 1: Upcoming Catalysts - A phase 1 trial for a key obesity program is expected to report data soon, which could serve as a catalyst for the stock price despite previous mixed results from Pfizer's obesity candidate, danuglipron [2][4] - The phase 2 clinical trial for the obesity program is anticipated to start before the end of 2024, which may further influence investor sentiment [3] Group 2: Leadership Changes - Pfizer is nearing the conclusion of its search for a new Chief Scientific Officer (CSO), following the current CSO's departure after 15 years, which could significantly impact the company's strategic R&D decisions [5][6] - The appointment of a new CSO could lead to a positive market reaction, indicating potential future upside for the stock as the new leader begins to influence the company's direction [8] Group 3: Activist Investor Dynamics - The activist investor group Starboard Value has taken a $1 billion stake in Pfizer, aiming to push for improved business performance and possibly a new CEO, creating a situation that could either escalate into public conflict or lead to beneficial changes for shareholders [10][11] - Addressing the concerns raised by Starboard, particularly regarding budgeting and forecasting processes, could result in immediate positive impacts for shareholders, such as more reliable guidance updates [12]

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in PFE over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Past per ...